Kornimate/medical-research-clean huggingface dataset:
impact of smoking information on concerns about radon

Conditions: Lung Neoplasms; Radon Exposure; Smoking; Intention; Risk Reduction Behavior

Summary: despite a push for tailored messages, health communications are often aimed at, and viewed by, people with varying levels of risk. this project examined-in the context of radon risk messages-whether information relevant to high-risk individuals can have an unintended influence on lower-risk individuals. specifically, the investigators assessed whether information about lung-cancer risk from smoking reduced concerns about lung-cancer risk from radon among nonsmokers. the investigators hypothesized that non-smokers who read a message that included smoking-relevant information would express less concern about the effects of radon exposure and less interest in testing their home compared to those who read a version in which smoking-relevant information was excluded. two studies were conducted. although the investigators did not exclude smokers, the focus was on participants self-identifying as nonsmokers (including never smokers and former smokers).

despite a push for tailored messages, health communications are often aimed at, and viewed by, people with varying levels of risk. this project examined-in the context of radon risk messages-whether information relevant to high-risk individuals can have an unintended influence on lower-risk individuals. specifically, the investigators assessed whether information about lung-cancer risk from smoking reduced concerns about lung-cancer risk from radon among nonsmokers. the investigators hypothesized that non-smokers who read a message that included smoking-relevant information would express less concern about the effects of radon exposure and less interest in testing their home compared to those who read a version in which smoking-relevant information was excluded. two studies were conducted. although the investigators did not exclude smokers, the focus was on participants self-identifying as nonsmokers (including never smokers and former smokers). participants in both studies were recruited through amazon's mechanical turk (mturk). participants viewed radon messages that varied in the information they communicated about smoking's effect on lung cancer. in study 1, smoking information was included or excluded from messages assembled from existing radon pamphlets. in study 2, versions of a new radon message either excluded smoking information, described smoking as a major cause of lung cancer, or also described smoking's synergistic effect with radon on lung cancer risk. after viewing a radon health message, participants completed a variety of measures. primary measures assessed respondents' anticipated sense of concern and related reactions if they learned that they/their home had been exposed to elevated levels of radon. other key measures included questions about participants' interest and intention to test their home for radon.

Eligibility criteria:
inclusion criteria: * live within the us * have an amazon mechanical turk account (website where online study was posted) exclusion criteria: * none

Keywords: risk perception
probiotics and breastmilk decrease risk of atopic dermatitis in premature infants

Conditions: Atopic Dermatitis

Summary: the purpose of this study is assess if the use of probiotic in very low weight could be other benefits a long time, as reduce atopic disease in this children.

in this study, the investigators analyse the influence of nutrition during the early neonatal period on the development and prevention of atopic dermatitis (ad) in children with a history of very low birth weight (vlbw). a retrospective cohort study was performed of vlbw preterm infants to assess the risk of their developing ad during childhood, according to nutrition with breastmilk and/or probiotic supplementation during the neonatal period. the analysis focused on nutritional and early childhood follow-up data for 437 newborns, of whom 184 received probiotics up to 36 weeks postmenstrual age. the neonatal history of the patients was consulted in their electronic medical records (gestacional age; birth weight; anthropometry at birth, first week and week 36 post menstrual age; nutricional management; administration of probiotics), and the presence of atopic diseases at school age was corroborated by telephone interviews. the descriptive date were summarized using medians and interquartile intervals for the continuous variables and distribution frequencies for the categorial variables. univariate comparisons were made by the mann-whitney test for the continuous variables and by the chi-square test for the categorical variables. the association of comorbidities in vlbw newborns and supplementation with one type or another of probiotic was evaluated with a multinomial regression analysis, ajustando por las variables que mostraron diferencias en el análisis de homogeneidad de los grupos de estudio. the analysis was performed using ibm spss 20.0 for windows software

Eligibility criteria:
inclusion criteria: * newborn with a gestational age \< or = 32 weeks and/or birth weight \< or = 1500 grams. exclusion criteria: * incomplete health history record o lack of data. * severe congenital anomalies.

Keywords: probiotics human breastmilk newborn very low birth weight atopic eczema
multimodal functional imaging combined with metabolomics in predicting the efficacy of ncrt for locally advanced escc

Conditions: Esophageal Squamous Cell Carcinoma

Summary: esophageal cancer (ec) is the seventh most frequently diagnosed cancers and the sixth leading causes of cancer death worldwide . it is one of the most common malignancy in china, with the third highest morbidity and mortality rate. more than 90% of patients with ec in china have esophageal squamous cell carcinoma (escc). neoadjuvant chemoradiotherapy (ncrt) followed by surgery is currently widely used strategy for locally advanced surgical ec. at present, conventional imaging methods have certain defects (focus only on the volume change) in the evaluation of the efficacy of ncrt. whereas functional imaging can more comprehensively reflect the biological and microstructural characterization of tumors. the changes of these aspects of tumors can be observed earlier than volumetric changes of tumors. the normal metabolism of the body is the basis for ensuring life activities. due to the increased energy demand and proliferation of tumor tissue in patients with cancer, the metabolism of patients is different from that of normal person. thus, the metabolic alterations seen in cancer cells have emerged as one of the hallmarks of cancer. previous metabolomic studies have demonstrated various metabolic alterations in patients with escc. many metabolites have been found to be promising diagnostic, staging or prognostic biomarkers for escc. however, there are few studies on metabolic markers on the chemoradiation sensitivity of esophageal cancer. therefore, the aim of the present study is to evaluate the value of functional imaging parameters and metabolic markers in assessing and predicting pathological response in patients who underwent ncrt for escc.


Eligibility criteria:
inclusion criteria: * pathologically confirmed esophageal squamous cell carcinoma； * ajcc 7th edition staging t3-t4a or n+； * no radiotherapy or chemotherapy in the past； * 18-75 years old； * hematology, biochemical and organ function indicators meet the following requirements: 1) white blood cells ≥ 3.0 x109/ l; 2)neutrophil cells ≥ 1.5 x109/ l; 3) platelet count ≥85 x109/l; 4) hemoglobin ≥90 g/l; 5) total bilirubin ≤1.5 times normal value; 6) alt≤ 1.5 x normal value; ast ≤1.5 times the normal value; 7) serum creatinine ≤1.5 times the normal value, and creatinine clearance rate (ccr) ≥60ml/min (cockcroft-gault); * ecog score 0-1 points; * able to eat a semi-liquid diet； * sign an informed consent. exclusion criteria: * have received radiotherapy or systemic chemotherapy; * during pregnancy or lactation; * uncontrollable serious medical diseases; * unable to sign informed consent; * with distant metastasis; * suffering from the second type of malignant tumor (except skin squamous cell carcinoma and carcinoma in situ of other organs) within the past 5 years； * those who cannot receive mri examination; * chemotherapy drugs or contrast agents allergic.

Keywords: neoadjuvant chemoradiotherapy esophageal squamous cell carcinoma multimodal functional imaging metabolomics
quality of life assessment of cryotherapy in esophageal or gastroesophageal cancer

Conditions: Esophageal Cancer

Summary: cryoablation combined with chemotherapy on the quality of life of patients with non resectable esophageal or gastroesophageal cancer.

this is a single arm prospective study to determine the effect of cryoablation combined with chemotherapy on the quality of life of patients with non resectable esophageal or gastroesophageal cancer.

Eligibility criteria:
inclusion criteria: * has esophageal or gastroesophageal cancer and will be receiving chemotherapy * dysphagia score of 1, 2, 3 or 4. * age ≥18 years old * american society of anesthesiologists (asa) physical status classification ≤ 4 * deemed not a candidate for esophageal cancer surgical resection * female subjects must be either post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control (i.e., total abstinence, birth control pills, an intrauterine device (iud), diaphragm, progesterone injections or implants, or condoms plus a spermicide) for the duration of the study exclusion criteria: * eastern cooperative oncology group (ecog) performance status greater than 2 * patient who received radiation treatment in the prior 8 weeks * known brain metastases causing cranial nerve deficits which can cause dysphagia * inability to undergo an esophagogastroduodenoscopy (egd) * pregnant or nursing * surgery or anatomy where capacity of stomach is reduced making cryotherapy contraindicated * patients with tracheoesophageal fistula

Keywords: cryotherapy palliation dysphagia
safety study of nk cells from sibship to treat the recurrence of hcc after liver transplantation

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to explore the safety of nk cells from sibship in patients with recurrent hepatocellular carcinoma after liver transplantation.

hepatocellular carcinoma (hcc) is one of the indications for the liver transplantation. with the advancement of liver transplantation associated science and technology, the recurrence of tumor posttransplantation has become the principal contradiction to worsen the prognosis and therefore the prevention of recurrence of hcc is the key to improve the efficacy of liver transplantation. adoptive cellular immunotherapy has been applied in various malignant tumors including hcc and has obtained significant effects. but for patients with liver transplant in immunosuppressed states, to successfully apply the immune cells to prevent and treat hcc relapse after liver transplantation must balance immunosuppression and anti-tumor immunity. it is necessary to consider the safety of adoptive cellular immunotherapy,and it is also necessary to consider the effectiveness of treatment that the immune cells in the immunosuppression state can exert anti-tumor effects. natural killer cells (nk cells) have mhc-unrestricted killing effect on malignant tumor cells and are not major mediating cells for gvhd, and might be an optimum choice to meet the above requirements. patients with confirmed recurrence of hepatocellular carcinoma after liver transplantation at the third affiliated hospital of sun yat-sen university were enrolled.participants in the study will be assigned to one of three treatment arms: arm a: participants will received conventional treatment and low dose of nk cells treatment for 4 times. arm b: participants will received conventional treatment and normal dose of nk cells treatment for 4 times. arm c: participants will received conventional treatment and normal dose of nk cells treatment for 8 times. the cultured nk cells from the peripheral blood of the same blood type were taken and infused at intervals of two weeks. periodic liver function recheck and imaging examination were conducted for 6 months after the last nk cells infusion.

Eligibility criteria:
inclusion criteria: * proved hepatocellular carcinoma histologically after liver transplantation. * confirmed recurrence of hepatocellular carcinoma by ct/mri. * the same blood type relatives with blood transmitted diseases negative. * written informed consent. exclusion criteria: * autoimmune diseases require long-term of glucocorticoid. * other candidates who are judged to be not applicable to this study by investigators. * poor compliance.

Keywords: nk cells liver transplantation hepatocellular carcinoma recurrence
a pilot study for ginkgolides meglumine injection skin testing.

Conditions: Allergy

Summary: this pilot study is designed to explore the optimal concentration and method of ginkgolides meglumine injection skin testing and to evaluate the value of skin test in predicting any possible allergic reactions to ginkgolides meglumine injection.

subjects will be enrolled in one of three groups with different doses to receive skin prick testing. then they may be arranged to receive intradermal, subcutaneous injection or intravenous tests with different doses.

Eligibility criteria:
inclusion criteria: * male and female between the ages of 18 and 70(inclusive)at the time of signing the informed consent form （icf）. * subjects meet any one of the following requirements * no history of using any dugs containing bilobalide, ginkgolide a, ginkgolide b, ginkgolide k (including ginkgolides meglumine injection). * history of using any dugs containing bilobalide, ginkgolide a, ginkgolide b, ginkgolide k (including ginkgolides meglumine injection), and no allergy. * history of allergy to any dugs contain bilobalide, ginkgolide a, ginkgolide b, ginkgolide k (including ginkgolides meglumine injection). * history of allergy to any other drugs. * willingness to participate in the study as evidenced by signing the informed consent form. exclusion criteria: * women in breastfeeding,menstrual or pregnancy period. * subjects are in the infectious disease, eczema, dermatitis, trauma,etc. * subjects meet any one of the following conditions * used β-blockers within 2 days prior to starting this study. * used h1 anti-histamines, imipramine, phenothiazine, beta adrenaline etc. within 1 week prior to starting this study. * used short-acting glucocorticoids drugs within 1 week prior to starting this study. * topical used glucocorticoids drugs within 2 weeks prior to starting this study. * used long-acting glucocorticoids drugs within 4 weeks prior to starting this study * subjects are currently participating or have participated in any other clinical trials within the prior 1 month of signing the icf. * subjects have a history of allergic shock. * subjects who are not suitable for this clinical trial at the discretion of the investigator.

Keywords: allergy skin test ginkgolides meglumine injection
step-it-up - peanut allergy study for infants

Conditions: Peanut Allergy; Food Allergy

Summary: multicenter randomized (1:1) trial of strict avoidance versus sub-threshold dietary introduction of peanut in peanut allergic infants 4-14 months of age who react at a minimum cumulative dose of at least 430 mg of peanut protein at initial oral food challenge (ofc) for 12 months, followed by cross-over to sub-threshold dietary introduction of peanut in those randomized initially to avoidance.


Eligibility criteria:
inclusion criteria: * children age 4-14 months suspected to be peanut allergic exclusion criteria: * significant medical problems

Keywords: infant food allergy treatment study peanut allergy treatment increase threshold of peanut intake for peanut allergic children
bioequivalence study of budesonide/formoterol easyhaler and symbicort turbohaler in asthmatics

Conditions: Asthma

Summary: the purpose of this study is to compare the test product budesonide/formoterol easyhaler with the marketed product symbicort turbohaler in terms of the drug absorbed into the bloodstream.


Eligibility criteria:
inclusion criteria: * males or females aged 18-60 years with documented diagnosis of asthma * prebronchodilator forced expiratory volume in one second (fev1) at least 80% of the predicted value * the asthma should be stable on the same regular treatment for at least 4 weeks before screening. exclusion criteria: * use of oral, parenteral or rectal corticosteroids within 4 weeks preceding the screening * respiratory infection within 4 weeks preceding the screening * any condition requiring regular concomitant treatment or likely to need concomitant treatment during the study with medicinal products which have pharmacokinetic interactions with budesonide * any disorder or clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of test results or cause a health risk for the subject if he/she participates in the study
detection of early idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: the purpose of the study is to determine if mir200 family may serve as a biomarker of ipf.


Eligibility criteria:
inclusion criteria for ipf patients: * informed consent * subjects ≥ 40 y.o. * naive patients with no ipf treatment * ipf diagnosis based on the ats/ers/jrs/alat criteria inclusion criteria for non-ipf ild patients: * informed consent * subjects ≥ 18 y.o. * ild diagnosis exclusion criteria: * hiv * hepatitis b * hepatitis c * pregnant or lactating women inclusion criteria for controls: informed consent \>18 years old; no lung diseases
acs monitoring charité berlin

Conditions: Compartment Syndromes

Summary: compartment syndrome is a very serious musculoskeletal disorder, which can lead to devastating consequences, such as limb amputation and life-threatening conditions. it is a well described medical condition considered to be an orthopaedic emergency affecting all ages. in the diagnosis of acute compartment syndrome, clinical suspicion supplemented by careful, repeated clinical examination continues to be the clinician's greatest tool. the classic signs and symptoms of acute compartment pressure are often listed as the 5 or 6 "ps": pain, pressure, pulselessness, paralysis, paresthesia, and pallor. the diagnosis is typically not made by using equipment and it is difficult in the awake and oriented patient, becoming even more problematic in the polytrauma patient. an alternative diagnostic method for compartment syndrome is invasive intra-compartmental pressure measurement via insertion of a pressure monitoring device into the muscle compartment. however, literature shows that commercially available intra compartmental pressure monitors have a highly variable intra-observer reproducibility and that user errors are common. compared to the invasive modalities or just experience of the surgeon, the cpmx1 shows promising advantages for the clinical application. not only is the technology used for the cpmx1 device safe and non-invasive for the patient with only initial training required for the healthcare professionals, but it has also demonstrated high intra- and inter-observer reproducibility (as per bench tests and confirmed in clinical setting). recently, two clinical studies ("swiss_evidence" and "swiss_clearance") were conducted using the cpmx1 in healthy volunteers in a real-world clinical environment. results of these studies confirmed that the application of the cmpx1 in patient care is safe and validated the reliability of compressibility ratio measurement with the cpmx1 in healthy volunteers. the use of the cpmx1 device therefore facilitates the measurements, as it is based on pre- existing ultrasound methods, and avoids any further risks to the patients compared to invasive compartmental pressure diagnosis methods.


Eligibility criteria:
inclusion criteria: * patients able to give consent * informed consent documented by signature * potential acute compartment syndrome (acs) of the extremities (excl. hands, feet) * male or female * age 18 to 95 years * intact skin at the measurement site * open fracture up to grade i if not in the measurement area exclusion criteria: * potential acute compartment syndrome (acs) of both extremities considered * limb anomalies that could hinder the measurement * individuals who are deprived of liberty pursuant to an administrative order or court order or approval.
study of autologous fat enhanced w/ regenerative cells transplanted to reconstruct breast deformities after lumpectomy

Conditions: Breast Neoplasms; Carcinoma, Ductal, Breast; Mammaplasty; Mastectomy, Segmental, Lumpectomy, Breast Reconstruction,

Summary: a post-marketing study evaluating the transplantation of autologous fat augmented with adipose derived regenerative cells (adrcs), in patients with functional and cosmetic breast deformities post segmental mastectomy or quadrantectomy (lumpectomy).


Eligibility criteria:
inclusion criteria: * females with a history of t2n0m0 breast carcinoma (tumor ≤3 cm in largest dimension) * surgical or endoscopic segmental mastectomy or quadrantectomy (lumpectomy) * clean surgical margins * no prosthesis in breast(s) to undergo treatment * ability to undergo lipoaspiration * last treatment for breast cancer ≥ 12 months prior to enrollment with absence of recurrence (patients on anti-estrogen adjuvant therapy are not excluded) * no evidence of recurrence of cancer based on mammogram or breast exam prior to enrollment * objective signs of mild breast damage post breast conservation therapy * type i cosmetic sequelae classification * a minimum of 1 cm of soft tissue (e.g. breast or fat) is available between the skin and chest wall at the recipient site * a minimum of two-thirds of the breast is remaining post breast conservation therapy * no continuous adhesion of skin to bone \>3 cm in diameter * the volume and shape of the defect(s) must be conducive to correction during a single treatment session (maximum defect volume ≤150 ml in breast(s) to undergo treatment) exclusion criteria: * history of autoimmune disorder (e.g., systemic lupus erythematosus \[sle\]) * history of connective, metabolic or atrophic skin disease * history of keloid scarring * chronic use (\>7 consecutive days) of anticoagulants (such as aspirin) or nsaids within 15 days prior to enrollment * life expectancy ≤ 2 years * recurrence or active malignancy requiring radiation or surgical treatment ≤12 months prior to enrollment * presence of any other known malignancy * body mass index (bmi) \>30 * plan to undergo weight reduction surgery or foresee any significant weight changes during the study (defined as changes in bmi \>5 compared to baseline * presence of contraindications to mri

Keywords: breast stem cell adipose derived stem cells adipose derived regenerative cells adrc reconstructive breast surgery breast reconstruction cancer carcinoma autologous fat transplantation autologous fat cosmetic breast deformities functional breast deformity lumpectomy segmental mastectomy quadrantectomy breast conservation therapy